{
    "abstract": "Post-authorisation safety studies (PASS) of vaccines assess or quantify the risk of adverse events following immunisation that were not identified or could not be estimated pre-licensure. The aim of this perspective paper is to describe the authors\u2019 experience in the design and conduct of twelve PASS that contributed to the evaluation of the benefit-risk of vaccines in real-world settings. We describe challenges and learnings from selected PASS of rotavirus, malaria, influenza, human papillomavirus and measles-mumps-rubella-varicella vaccines that assessed or identified potential or theoretical risks, which may lead to changes to risk management plans and/or to label updates. Study settings include the use of large healthcare databases and de novo data collection. PASS methodology is influenced by the background incidence of the outcome of interest, vaccine uptake, availability and quality of data sources, identification of the at-risk population and of suitable comparators, availability of validated case definitions, and the frequent need for case ascertainment in large databases. Challenges include the requirement for valid exposure and outcome data, identification of, and access to, adequate data sources, and mitigating limitations including bias and confounding. Assessing feasibility is becoming a key step to confirm that study objectives can be met in a timely manner. PASS provide critical information for regulators, public health agencies, vaccine manufacturers and ultimately, individuals. Collaborative approaches and synergistic efforts between vaccine manufacturers and key stakeholders, such as regulatory and public health agencies, are needed to facilitate access to data, and to drive optimal study design and implementation, with the aim of generating robust evidence.",
    "author_highlights": [
        {
            "endOffset": 20495,
            "sentence": "PASS evaluate identified, potential or theoretical risks of medicinal products.",
            "startOffset": 20416
        },
        {
            "endOffset": 20578,
            "sentence": "PASS contribute to the benefit-risk evaluation of vaccines in real-world settings.",
            "startOffset": 20496
        },
        {
            "endOffset": 20662,
            "sentence": "Development of PASS is supported by recently revised pharmacovigilance regulations.",
            "startOffset": 20579
        },
        {
            "endOffset": 20745,
            "sentence": "Methodological issues are described and can be mitigated by assessing feasibility.",
            "startOffset": 20663
        },
        {
            "endOffset": 20814,
            "sentence": "Collaborative approaches facilitate optimal PASS design and conduct.",
            "startOffset": 20746
        },
        {
            "endOffset": 20898,
            "sentence": "Examples are translated into generic concepts of interest to the vaccine community.",
            "startOffset": 20815
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Black"
                }
            ],
            "doi": "10.1586/14760584.2015.1091733",
            "firstpage": "1543",
            "issn": "14760584",
            "lastpage": "1548",
            "pmid": "26414015",
            "pub_year": 2015,
            "title": "The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials",
            "volume": "14"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Fernanda Tavares",
                    "initial": "F.T.",
                    "last": "da Silva"
                },
                {
                    "first": "Alberta",
                    "initial": "A.",
                    "last": "Di Pasquale"
                },
                {
                    "first": "Juan P.",
                    "initial": "J.P.",
                    "last": "Yarzabal"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Gar\u00e7on"
                }
            ],
            "doi": "10.1080/21645515.2015.1043501",
            "firstpage": "1814",
            "issn": "21645515",
            "lastpage": "1824",
            "pmid": "26029975",
            "pub_year": 2015,
            "title": "Safety assessment of adjuvanted vaccines: Methodological considerations",
            "volume": "11"
        },
        "b0015": null,
        "b0020": null,
        "b0025": null,
        "b0030": {
            "authors": [
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Arlett"
                },
                {
                    "first": "Geraldine",
                    "initial": "G.",
                    "last": "Portier"
                },
                {
                    "first": "Roberto",
                    "initial": "R.",
                    "last": "De Lisa"
                },
                {
                    "first": "Kevin",
                    "initial": "K.",
                    "last": "Blake"
                },
                {
                    "first": "Noel",
                    "initial": "N.",
                    "last": "Wathion"
                },
                {
                    "first": "Jean Michel",
                    "initial": "J.M.",
                    "last": "Dogne"
                },
                {
                    "first": "Almath",
                    "initial": "A.",
                    "last": "Spooner"
                },
                {
                    "first": "June",
                    "initial": "J.",
                    "last": "Raine"
                },
                {
                    "first": "Guido",
                    "initial": "G.",
                    "last": "Rasi"
                }
            ],
            "doi": "10.1038/nrd3713-c1",
            "firstpage": "395",
            "issn": "14741776",
            "lastpage": "397",
            "pmid": "24751815",
            "pub_year": 2014,
            "title": "Proactively managing the risk of marketed drugs: Experience with the EMA Pharmacovigilance Risk Assessment Committee",
            "volume": "13"
        },
        "b0035": {
            "authors": [
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Hallas"
                }
            ],
            "doi": "10.1002/pds.3891",
            "firstpage": "2",
            "issn": "10538569",
            "lastpage": "10",
            "pmid": "26537534",
            "pub_year": 2016,
            "title": "Guidelines for good pharmacoepidemiology practice (GPP)",
            "volume": "25"
        },
        "b0040": null,
        "b0045": {
            "authors": [],
            "firstpage": "1007",
            "issn": "01492195",
            "pmid": "10577495",
            "pub_year": 1999,
            "title": "Withdrawal of rotavirus vaccine recommendation.",
            "volume": "48"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Guillermo M.",
                    "initial": "G.M.",
                    "last": "Ruiz-Palacios"
                },
                {
                    "first": "Irene",
                    "initial": "I.",
                    "last": "P\u00e9rez-Schael"
                },
                {
                    "first": "F. Ra\u00fal",
                    "initial": "F.R.",
                    "last": "Vel\u00e1zquez"
                },
                {
                    "first": "Hector",
                    "initial": "H.",
                    "last": "Abate"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Breuer"
                },
                {
                    "first": "Sue Ann Costa",
                    "initial": "S.A.C.",
                    "last": "Clemens"
                },
                {
                    "first": "Brigitte",
                    "initial": "B.",
                    "last": "Cheuvart"
                },
                {
                    "first": "Felix",
                    "initial": "F.",
                    "last": "Espinoza"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Gillard"
                },
                {
                    "first": "Bruce L.",
                    "initial": "B.L.",
                    "last": "Innis"
                },
                {
                    "first": "Yolanda",
                    "initial": "Y.",
                    "last": "Cervantes"
                },
                {
                    "first": "Alexandre C.",
                    "initial": "A.C.",
                    "last": "Linhares"
                },
                {
                    "first": "P\u00edo",
                    "initial": "P.",
                    "last": "L\u00f3pez"
                },
                {
                    "first": "Mercedes",
                    "initial": "M.",
                    "last": "Mac\u00edas-Parra"
                },
                {
                    "first": "Eduardo",
                    "initial": "E.",
                    "last": "Ortega-Barr\u00eda"
                },
                {
                    "first": "Vesta",
                    "initial": "V.",
                    "last": "Richardson"
                },
                {
                    "first": "Doris Maribel",
                    "initial": "D.M.",
                    "last": "Rivera-Medina"
                },
                {
                    "first": "Luis",
                    "initial": "L.",
                    "last": "Rivera"
                },
                {
                    "first": "Bel\u00e9n",
                    "initial": "B.",
                    "last": "Salinas"
                },
                {
                    "first": "Noris",
                    "initial": "N.",
                    "last": "Pav\u00eda-Ruz"
                },
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Salmer\u00f3n"
                },
                {
                    "first": "Ricardo",
                    "initial": "R.",
                    "last": "R\u00fcttimann"
                },
                {
                    "first": "Juan Carlos",
                    "initial": "J.C.",
                    "last": "Tinoco"
                },
                {
                    "first": "Pilar",
                    "initial": "P.",
                    "last": "Rubio"
                },
                {
                    "first": "Ernesto",
                    "initial": "E.",
                    "last": "Nu\u00f1ez"
                },
                {
                    "first": "M. Lourdes",
                    "initial": "M.L.",
                    "last": "Guerrero"
                },
                {
                    "first": "Juan Pablo",
                    "initial": "J.P.",
                    "last": "Yarz\u00e1bal"
                },
                {
                    "first": "Silvia",
                    "initial": "S.",
                    "last": "Damaso"
                },
                {
                    "first": "Nadia",
                    "initial": "N.",
                    "last": "Tornieporth"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "S\u00e1ez-Llorens"
                },
                {
                    "first": "Rodrigo F.",
                    "initial": "R.F.",
                    "last": "Vergara"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Alain",
                    "initial": "A.",
                    "last": "Bouckenooghe"
                },
                {
                    "first": "Ralf",
                    "initial": "R.",
                    "last": "Clemens"
                },
                {
                    "first": "B\u00e9atrice",
                    "initial": "B.",
                    "last": "De Vos"
                },
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "O'Ryan"
                }
            ],
            "doi": "10.1056/NEJMoa052434",
            "firstpage": "11",
            "issn": "00284793",
            "lastpage": "22",
            "pmid": "16394298",
            "pub_year": 2006,
            "title": "Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis",
            "volume": "354"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Robbin",
                    "initial": "R.",
                    "last": "Itzler"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Karvonen"
                },
                {
                    "first": "Tiina",
                    "initial": "T.",
                    "last": "Korhonen"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Van Damme"
                },
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Behre"
                },
                {
                    "first": "Gianni",
                    "initial": "G.",
                    "last": "Bona"
                },
                {
                    "first": "Leif",
                    "initial": "L.",
                    "last": "Gothefors"
                },
                {
                    "first": "Penny M.",
                    "initial": "P.M.",
                    "last": "Heaton"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Dallas"
                },
                {
                    "first": "Michelle G.",
                    "initial": "M.G.",
                    "last": "Goveia"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.10.041",
            "firstpage": "345",
            "issn": "0264410X",
            "lastpage": "351",
            "pmid": "19879226",
            "pub_year": 2009,
            "title": "RotaTeq\u00ae, a pentavalent rotavirus vaccine: Efficacy and safety among infants in Europe",
            "volume": "28"
        },
        "b0060": {
            "authors": [
                {
                    "first": "F. Ra\u00fal",
                    "initial": "F.R.",
                    "last": "Vel\u00e1zquez"
                },
                {
                    "first": "Romulo E.",
                    "initial": "R.E.",
                    "last": "Colindres"
                },
                {
                    "first": "Concepci\u00f3n",
                    "initial": "C.",
                    "last": "Grajales"
                },
                {
                    "first": "M. Teresa",
                    "initial": "M.T.",
                    "last": "Hern\u00e1ndez"
                },
                {
                    "first": "Mar\u00eda Guadalupe",
                    "initial": "M.G.",
                    "last": "Mercadillo"
                },
                {
                    "first": "F. Javier",
                    "initial": "F.J.",
                    "last": "Torres"
                },
                {
                    "first": "Mariayolanda",
                    "initial": "M.",
                    "last": "Cervantes-Apolinar"
                },
                {
                    "first": "Rodrigo",
                    "initial": "R.",
                    "last": "Deantonio-Suarez"
                },
                {
                    "first": "Eduardo",
                    "initial": "E.",
                    "last": "Ortega-Barria"
                },
                {
                    "first": "Maxim",
                    "initial": "M.",
                    "last": "Blum"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Breuer"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Verstraeten"
                }
            ],
            "doi": "10.1097/INF.0b013e318253add3",
            "firstpage": "736",
            "issn": "08913668",
            "lastpage": "744",
            "pmid": "22695189",
            "pub_year": 2012,
            "title": "Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico",
            "volume": "31"
        },
        "b0065": null,
        "b0070": {
            "authors": [
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Rosillon"
                },
                {
                    "first": "Hubert",
                    "initial": "H.",
                    "last": "Buyse"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Su Peing",
                    "initial": "S.P.",
                    "last": "Ng"
                },
                {
                    "first": "F. Ra\u00fal",
                    "initial": "F.R.",
                    "last": "Vel\u00e1zquez"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Breuer"
                }
            ],
            "doi": "10.1097/INF.0000000000000715",
            "firstpage": "763",
            "issn": "08913668",
            "lastpage": "768",
            "pmid": "26069948",
            "pub_year": 2015,
            "title": "Risk of intussusception after rotavirus vaccination: Meta-analysis of postlicensure studies",
            "volume": "34"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Rui",
                    "initial": "R.",
                    "last": "Dong"
                },
                {
                    "first": "Yi Fan",
                    "initial": "Y.F.",
                    "last": "Yang"
                },
                {
                    "first": "Gong",
                    "initial": "G.",
                    "last": "Chen"
                },
                {
                    "first": "Zhen",
                    "initial": "Z.",
                    "last": "Shen"
                },
                {
                    "first": "Shan",
                    "initial": "S.",
                    "last": "Zheng"
                }
            ],
            "firstpage": "1306",
            "issn": "19405901",
            "lastpage": "1313",
            "pub_year": 2016,
            "title": "Risk of intussusception after rotavirus vaccination: A meta-analysis",
            "volume": "9"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Andy",
                    "initial": "A.",
                    "last": "Clark"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Jit"
                },
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "Christina",
                    "initial": "C.",
                    "last": "Atchison"
                },
                {
                    "first": "W. John",
                    "initial": "W.J.",
                    "last": "Edmunds"
                },
                {
                    "first": "Colin",
                    "initial": "C.",
                    "last": "Sanderson"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.04.082",
            "firstpage": "3604",
            "issn": "0264410X",
            "lastpage": "3610",
            "pmid": "24814524",
            "pub_year": 2014,
            "title": "Evaluating the potential risks and benefits of infant rotavirus vaccination in England",
            "volume": "32"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Czajka"
                },
                {
                    "first": "Volker",
                    "initial": "V.",
                    "last": "Schuster"
                },
                {
                    "first": "Fred",
                    "initial": "F.",
                    "last": "Zepp"
                },
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "Martine",
                    "initial": "M.",
                    "last": "Douha"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Willems"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.07.076",
            "firstpage": "6504",
            "issn": "0264410X",
            "lastpage": "6511",
            "pmid": "19665608",
            "pub_year": 2009,
            "title": "A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra\u2122): Immunogenicity and safety profile",
            "volume": "27"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Steven J.",
                    "initial": "S.J.",
                    "last": "Jacobsen"
                },
                {
                    "first": "Bradley K.",
                    "initial": "B.K.",
                    "last": "Ackerson"
                },
                {
                    "first": "Lina S.",
                    "initial": "L.S.",
                    "last": "Sy"
                },
                {
                    "first": "Trung N.",
                    "initial": "T.N.",
                    "last": "Tran"
                },
                {
                    "first": "Tonia L.",
                    "initial": "T.L.",
                    "last": "Jones"
                },
                {
                    "first": "Janis F.",
                    "initial": "J.F.",
                    "last": "Yao"
                },
                {
                    "first": "Fagen",
                    "initial": "F.",
                    "last": "Xie"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Craig Cheetham"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Saddier"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.05.056",
            "firstpage": "4656",
            "issn": "0264410X",
            "lastpage": "4661",
            "pmid": "19520201",
            "pub_year": 2009,
            "title": "Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting",
            "volume": "27"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Tania",
                    "initial": "T.",
                    "last": "Schink"
                },
                {
                    "first": "Jakob",
                    "initial": "J.",
                    "last": "Holstiege"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Kowalzik"
                },
                {
                    "first": "Fred",
                    "initial": "F.",
                    "last": "Zepp"
                },
                {
                    "first": "Edeltraut",
                    "initial": "E.",
                    "last": "Garbe"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.12.011",
            "firstpage": "645",
            "issn": "0264410X",
            "lastpage": "650",
            "pmid": "24374498",
            "pub_year": 2014,
            "title": "Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination",
            "volume": "32"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Bauchau"
                },
                {
                    "first": "Lionel",
                    "initial": "L.",
                    "last": "Van Holle"
                },
                {
                    "first": "Carine",
                    "initial": "C.",
                    "last": "Cohen"
                }
            ],
            "doi": "10.1007/s40264-015-0326-4",
            "firstpage": "1095",
            "issn": "01145916",
            "lastpage": "1102",
            "pmid": "26251259",
            "pub_year": 2015,
            "title": "Modelling Hospitalisation Ratios for Febrile Convulsions and Severe Varicella Under Combined Measles, Mumps, Rubella, and Varicella (MMRV\u2014Priorix-Tetra\u2122) Compared to Separate MMR\u00a0+\u00a0V Vaccination",
            "volume": "38"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Sholom",
                    "initial": "S.",
                    "last": "Wacholder"
                },
                {
                    "first": "Bingshu Eric",
                    "initial": "B.E.",
                    "last": "Chen"
                },
                {
                    "first": "Allen",
                    "initial": "A.",
                    "last": "Wilcox"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Macones"
                },
                {
                    "first": "Paula",
                    "initial": "P.",
                    "last": "Gonzalez"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Befano"
                },
                {
                    "first": "Allan",
                    "initial": "A.",
                    "last": "Hildesheim"
                },
                {
                    "first": "Ana Cecilia",
                    "initial": "A.C.",
                    "last": "Rodr\u00edguez"
                },
                {
                    "first": "Diane",
                    "initial": "D.",
                    "last": "Solomon"
                },
                {
                    "first": "Rolando",
                    "initial": "R.",
                    "last": "Herrero"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Schiffman"
                }
            ],
            "doi": "10.1136/bmj.c712",
            "firstpage": "696",
            "issn": "17561833",
            "pmid": "20197322",
            "pub_year": 2010,
            "title": "Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: Pooled analysis of two randomised controlled trials",
            "volume": "340"
        },
        "b0110": null,
        "b0115": {
            "authors": [
                {
                    "first": "Emily",
                    "initial": "E.",
                    "last": "Herrett"
                },
                {
                    "first": "Arlene M.",
                    "initial": "A.M.",
                    "last": "Gallagher"
                },
                {
                    "first": "Krishnan",
                    "initial": "K.",
                    "last": "Bhaskaran"
                },
                {
                    "first": "Harriet",
                    "initial": "H.",
                    "last": "Forbes"
                },
                {
                    "first": "Rohini",
                    "initial": "R.",
                    "last": "Mathur"
                },
                {
                    "first": "Tjeerd van",
                    "initial": "T.v.",
                    "last": "Staa"
                },
                {
                    "first": "Liam",
                    "initial": "L.",
                    "last": "Smeeth"
                }
            ],
            "doi": "10.1093/ije/dyv098",
            "firstpage": "827",
            "issn": "03005771",
            "lastpage": "836",
            "pmid": "26050254",
            "pub_year": 2015,
            "title": "Data Resource Profile: Clinical Practice Research Datalink (CPRD)",
            "volume": "44"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Baril"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Rosillon"
                },
                {
                    "first": "Corinne",
                    "initial": "C.",
                    "last": "Willame"
                },
                {
                    "first": "Maria Genalin",
                    "initial": "M.G.",
                    "last": "Angelo"
                },
                {
                    "first": "Julia",
                    "initial": "J.",
                    "last": "Zima"
                },
                {
                    "first": "Judith H.",
                    "initial": "J.H.",
                    "last": "van den Bosch"
                },
                {
                    "first": "Tjeerd",
                    "initial": "T.",
                    "last": "Van Staa"
                },
                {
                    "first": "Rachael",
                    "initial": "R.",
                    "last": "Boggon"
                },
                {
                    "first": "Eveline M.",
                    "initial": "E.M.",
                    "last": "Bunge"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Hernandez-Diaz"
                },
                {
                    "first": "Christina D.",
                    "initial": "C.D.",
                    "last": "Chambers"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.07.024",
            "firstpage": "6884",
            "issn": "0264410X",
            "lastpage": "6891",
            "pmid": "26206268",
            "pub_year": 2015,
            "title": "Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom",
            "volume": "33"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Lu\u00edsa E\u00e7a",
                    "initial": "L.E.",
                    "last": "Guimar\u00e3es"
                },
                {
                    "first": "Britain",
                    "initial": "B.",
                    "last": "Baker"
                },
                {
                    "first": "Carlo",
                    "initial": "C.",
                    "last": "Perricone"
                },
                {
                    "first": "Yehuda",
                    "initial": "Y.",
                    "last": "Shoenfeld"
                }
            ],
            "doi": "10.1016/j.phrs.2015.08.003",
            "firstpage": "190",
            "issn": "10436618",
            "lastpage": "209",
            "pmid": "26275795",
            "pub_year": 2015,
            "title": "Vaccines, adjuvants and autoimmunity",
            "volume": "100"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Fernanda",
                    "initial": "F.",
                    "last": "Tavares Da Silva"
                },
                {
                    "first": "Filip",
                    "initial": "F.",
                    "last": "De Keyser"
                },
                {
                    "first": "Paul Henri",
                    "initial": "P.H.",
                    "last": "Lambert"
                },
                {
                    "first": "William H.",
                    "initial": "W.H.",
                    "last": "Robinson"
                },
                {
                    "first": "Ren\u00e9",
                    "initial": "R.",
                    "last": "Westhovens"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Sindic"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.01.042",
            "firstpage": "1870",
            "issn": "0264410X",
            "lastpage": "1876",
            "pmid": "23391600",
            "pub_year": 2013,
            "title": "Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines",
            "volume": "31"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Chun",
                    "initial": "C.",
                    "last": "Chao"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Jacobsen"
                }
            ],
            "doi": "10.4161/hv.21268",
            "firstpage": "1302",
            "issn": "2164554X",
            "lastpage": "1304",
            "pmid": "22871958",
            "pub_year": 2012,
            "title": "Evaluation of autoimmune safety signal in observational vaccine safety studies",
            "volume": "8"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Corinne",
                    "initial": "C.",
                    "last": "Willame"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Rosillon"
                },
                {
                    "first": "Julia",
                    "initial": "J.",
                    "last": "Zima"
                },
                {
                    "first": "Maria Genalin",
                    "initial": "M.G.",
                    "last": "Angelo"
                },
                {
                    "first": "Anke L.",
                    "initial": "A.L.",
                    "last": "Stuurman"
                },
                {
                    "first": "Hilde",
                    "initial": "H.",
                    "last": "Vroling"
                },
                {
                    "first": "Rachael",
                    "initial": "R.",
                    "last": "Boggon"
                },
                {
                    "first": "Eveline M.",
                    "initial": "E.M.",
                    "last": "Bunge"
                },
                {
                    "first": "Manel",
                    "initial": "M.",
                    "last": "Pladevall-Vila"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Baril"
                }
            ],
            "doi": "10.1080/21645515.2016.1199308",
            "firstpage": "2862",
            "issn": "21645515",
            "lastpage": "2871",
            "pmid": "27428517",
            "pub_year": 2016,
            "title": "Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom",
            "volume": "12"
        },
        "b0145": null,
        "b0150": null,
        "b0155": {
            "authors": [
                {
                    "first": "David W.",
                    "initial": "D.W.",
                    "last": "Vaughn"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Seifert"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Hepburn"
                },
                {
                    "first": "Walthere",
                    "initial": "W.",
                    "last": "Dewe"
                },
                {
                    "first": "Ping",
                    "initial": "P.",
                    "last": "Li"
                },
                {
                    "first": "Mamadou",
                    "initial": "M.",
                    "last": "Drame"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Cohet"
                },
                {
                    "first": "Bruce L.",
                    "initial": "B.L.",
                    "last": "Innis"
                },
                {
                    "first": "Louis F.",
                    "initial": "L.F.",
                    "last": "Fries"
                }
            ],
            "doi": "10.4161/21645515.2014.972149",
            "firstpage": "2942",
            "issn": "21645515",
            "lastpage": "2957",
            "pmid": "25483467",
            "pub_year": 2014,
            "title": "Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 in fluenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials",
            "volume": "10"
        },
        "b0160": null,
        "b0165": {
            "authors": [
                {
                    "first": "Irwin",
                    "initial": "I.",
                    "last": "Nazareth"
                },
                {
                    "first": "Fernanda",
                    "initial": "F.",
                    "last": "Tavares"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Rosillon"
                },
                {
                    "first": "Fran\u00e7ois",
                    "initial": "F.",
                    "last": "Haguinet"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Bauchau"
                }
            ],
            "doi": "10.1136/bmjopen-2012-001912",
            "issn": "20446055",
            "pub_year": 2013,
            "title": "Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: A prospective cohort study",
            "volume": "3"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Fernanda",
                    "initial": "F.",
                    "last": "Tavares"
                },
                {
                    "first": "Irwin",
                    "initial": "I.",
                    "last": "Nazareth"
                },
                {
                    "first": "Javier Sawchik",
                    "initial": "J.S.",
                    "last": "Monegal"
                },
                {
                    "first": "Ida",
                    "initial": "I.",
                    "last": "Kolte"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Verstraeten"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Bauchau"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.04.114",
            "firstpage": "6358",
            "issn": "0264410X",
            "lastpage": "6365",
            "pmid": "21596080",
            "pub_year": 2011,
            "title": "Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: A prospective cohort study",
            "volume": "29"
        },
        "b0175": null,
        "b0180": null,
        "b0185": {
            "authors": [
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Cohet"
                },
                {
                    "first": "Fran\u00e7ois",
                    "initial": "F.",
                    "last": "Haguinet"
                },
                {
                    "first": "Ga\u00ebl Dos",
                    "initial": "G.D.",
                    "last": "Santos"
                },
                {
                    "first": "Dave",
                    "initial": "D.",
                    "last": "Webb"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Logie"
                },
                {
                    "first": "Germano L.C.",
                    "initial": "G.L.C.",
                    "last": "Ferreira"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Rosillon"
                },
                {
                    "first": "Vivek",
                    "initial": "V.",
                    "last": "Shinde"
                }
            ],
            "doi": "10.1136/bmjopen-2015-009264",
            "issn": "20446055",
            "pmid": "26823177",
            "pub_year": 2016,
            "title": "Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: A self-controlled case series",
            "volume": "6"
        },
        "b0190": {
            "authors": [
                {
                    "first": "Ga\u00ebl",
                    "initial": "G.",
                    "last": "Dos Santos"
                },
                {
                    "first": "Harry A.",
                    "initial": "H.A.",
                    "last": "Seifert"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Bauchau"
                },
                {
                    "first": "Vivek",
                    "initial": "V.",
                    "last": "Shinde"
                },
                {
                    "first": "Dominique M.",
                    "initial": "D.M.",
                    "last": "Barbeau"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Cohet"
                }
            ],
            "doi": "10.1007/s40264-017-0532-3",
            "firstpage": "693",
            "issn": "01145916",
            "lastpage": "702",
            "pmid": "28417321",
            "pub_year": 2017,
            "title": "Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt",
            "volume": "40"
        },
        "b0195": {
            "authors": [
                {
                    "first": "Miriam C.J.M.",
                    "initial": "M.C.J.M.",
                    "last": "Sturkenboom"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.03.026",
            "firstpage": "B6",
            "issn": "0264410X",
            "lastpage": "B13",
            "pmid": "26022571",
            "pub_year": 2015,
            "title": "The narcolepsy-pandemic influenza story: Can the truth ever be unraveled?",
            "volume": "33"
        },
        "b0200": {
            "authors": [
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Verstraeten"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Cohet"
                },
                {
                    "first": "Ga\u00ebl",
                    "initial": "G.",
                    "last": "Dos Santos"
                },
                {
                    "first": "Germano L.C.",
                    "initial": "G.L.C.",
                    "last": "Ferreira"
                },
                {
                    "first": "Kaatje",
                    "initial": "K.",
                    "last": "Bollaerts"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Bauchau"
                },
                {
                    "first": "Vivek",
                    "initial": "V.",
                    "last": "Shinde"
                }
            ],
            "doi": "10.1080/21645515.2015.1068486",
            "firstpage": "187",
            "issn": "21645515",
            "lastpage": "193",
            "pmid": "26379011",
            "pub_year": 2016,
            "title": "PandemrixTM and narcolepsy: A critical appraisal of the observational studies",
            "volume": "12"
        },
        "b0205": {
            "authors": [
                {
                    "first": "Jacques",
                    "initial": "J.",
                    "last": "Montplaisir"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Petit"
                },
                {
                    "first": "Marie Jos\u00e9e",
                    "initial": "M.J.",
                    "last": "Quinn"
                },
                {
                    "first": "Manale",
                    "initial": "M.",
                    "last": "Ouakki"
                },
                {
                    "first": "Genevi\u00e8ve",
                    "initial": "G.",
                    "last": "Deceuninck"
                },
                {
                    "first": "Alex",
                    "initial": "A.",
                    "last": "Desautels"
                },
                {
                    "first": "Emmanuel",
                    "initial": "E.",
                    "last": "Mignot"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "De Wals"
                }
            ],
            "doi": "10.1371/journal.pone.0108489",
            "issn": "19326203",
            "pmid": "25264897",
            "pub_year": 2014,
            "title": "Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec",
            "volume": "9"
        },
        "b0210": null,
        "b0215": {
            "authors": [
                {
                    "first": "Ali",
                    "initial": "A.",
                    "last": "Rowhani-Rahbar"
                },
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Cornelia L.",
                    "initial": "C.L.",
                    "last": "Dekker"
                },
                {
                    "first": "Kathryn M.",
                    "initial": "K.M.",
                    "last": "Edwards"
                },
                {
                    "first": "Colin D.",
                    "initial": "C.D.",
                    "last": "Marchant"
                },
                {
                    "first": "Claudia",
                    "initial": "C.",
                    "last": "Vellozzi"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Fireman"
                },
                {
                    "first": "James J.",
                    "initial": "J.J.",
                    "last": "Sejvar"
                },
                {
                    "first": "Neal A.",
                    "initial": "N.A.",
                    "last": "Halsey"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.07.024",
            "firstpage": "271",
            "issn": "0264410X",
            "lastpage": "277",
            "pmid": "22835735",
            "pub_year": 2012,
            "title": "Biologically plausible and evidence-based risk intervals in immunization safety research",
            "volume": "31"
        },
        "b0220": {
            "authors": [
                {
                    "first": "Vera",
                    "initial": "V.",
                    "last": "Ehrenstein"
                },
                {
                    "first": "Irene",
                    "initial": "I.",
                    "last": "Petersen"
                },
                {
                    "first": "Liam",
                    "initial": "L.",
                    "last": "Smeeth"
                },
                {
                    "first": "Susan S.",
                    "initial": "S.S.",
                    "last": "Jick"
                },
                {
                    "first": "Eric I.",
                    "initial": "E.I.",
                    "last": "Benchimol"
                },
                {
                    "first": "Jonas F.",
                    "initial": "J.F.",
                    "last": "Ludvigsson"
                },
                {
                    "first": "Henrik Toft",
                    "initial": "H.T.",
                    "last": "S\u00f8rensen"
                }
            ],
            "doi": "10.2147/CLEP.S104448",
            "firstpage": "49",
            "issn": "11791349",
            "lastpage": "51",
            "pub_year": 2016,
            "title": "Helping everyone do better: A call for validation studies of routinely recorded health data",
            "volume": "8"
        },
        "b0225": {
            "authors": [
                {
                    "first": "Corinne",
                    "initial": "C.",
                    "last": "Willame"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Baril"
                },
                {
                    "first": "Judith",
                    "initial": "J.",
                    "last": "van den Bosch"
                },
                {
                    "first": "Germano L.C.",
                    "initial": "G.L.C.",
                    "last": "Ferreira"
                },
                {
                    "first": "Rachael",
                    "initial": "R.",
                    "last": "Williams"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Rosillon"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Cohet"
                }
            ],
            "doi": "10.1002/pds.4081",
            "firstpage": "1397",
            "issn": "10538569",
            "lastpage": "1406",
            "pmid": "27601179",
            "pub_year": 2016,
            "title": "Importance of feasibility assessments before implementing non-interventional pharmacoepidemiologic studies of vaccines: lessons learned and recommendations for future studies",
            "volume": "25"
        },
        "b0230": {
            "authors": [
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Bonhoeffer"
                },
                {
                    "first": "Steve",
                    "initial": "S.",
                    "last": "Black"
                },
                {
                    "first": "Hector",
                    "initial": "H.",
                    "last": "Izurieta"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Zuber"
                },
                {
                    "first": "Miriam",
                    "initial": "M.",
                    "last": "Sturkenboom"
                }
            ],
            "doi": "10.1016/j.biologicals.2012.07.007",
            "firstpage": "393",
            "issn": "10451056",
            "lastpage": "397",
            "pmid": "22902972",
            "pub_year": 2012,
            "title": "Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe",
            "volume": "40"
        },
        "b0235": null,
        "b0240": {
            "authors": [
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Kurz"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Bauchau"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Mahy"
                },
                {
                    "first": "Steffen",
                    "initial": "S.",
                    "last": "Glismann"
                },
                {
                    "first": "Lieke Maria",
                    "initial": "L.M.",
                    "last": "van der Aa"
                },
                {
                    "first": "Fran\u00e7ois",
                    "initial": "F.",
                    "last": "Simondon"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.02.039",
            "firstpage": "1844",
            "issn": "0264410X",
            "lastpage": "1855",
            "pmid": "28285984",
            "pub_year": 2017,
            "title": "The ADVANCE Code of Conduct for collaborative vaccine studies",
            "volume": "35"
        },
        "b0245": null,
        "b0250": null
    },
    "body_text": [
        {
            "endOffset": 39976,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 39922,
                    "startOffset": 39915
                },
                "b0185": {
                    "endOffset": 39975,
                    "startOffset": 39971
                },
                "b0215": {
                    "endOffset": 39922,
                    "startOffset": 39915
                }
            },
            "secId": "s0085",
            "sentence": "Post-immunisation risk periods with biologically plausible timeframes are an important design component [26,43] but were often based on theoretical assumptions [37].",
            "startOffset": 39811,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 26517,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0020",
            "sentence": "An attributable risk of 3\u20134 additional IS cases per 100,000 vaccinated infants was observed.",
            "startOffset": 26425,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 31338,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0030",
                    "title": "Investigating a potential risk identified prior to licensure"
                }
            ],
            "secId": "s0035",
            "sentence": "Patient profiles, including free text, were reviewed by experts blinded to vaccination status.",
            "startOffset": 31244,
            "title": "AS04-adjuvanted human papillomavirus (HPV) vaccine and spontaneous abortion (SA)"
        },
        {
            "endOffset": 32494,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0040",
                    "title": "Investigating a theoretical risk"
                }
            ],
            "secId": "s0045",
            "sentence": "An exposed cohort, an unexposed historical cohort, an unexposed concurrent male cohort, and an unexposed historical male cohort, were defined.",
            "startOffset": 32352,
            "title": "HPV vaccine and autoimmune diseases"
        },
        {
            "endOffset": 28355,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "refoffsets": {
                "b0085": {
                    "endOffset": 28354,
                    "startOffset": 28350
                }
            },
            "secId": "s0025",
            "sentence": "During the clinical development of the combined live-attenuated MMRV vaccine (Priorix tetra, GSK) the incidence of fever after the first, but not the second, vaccine dose was 1.5-fold higher compared to measles-mumps-rubella (MMR) and varicella (MMR+V) vaccines administered separately [17].",
            "startOffset": 28064,
            "title": "Measles-mumps-rubella-varicella (MMRV) vaccine and febrile convulsion (FC)"
        },
        {
            "endOffset": 26424,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0020",
            "sentence": "A prospective self-controlled case-series built on the active IS surveillance already in place, on the fact that Rotarix was the only rotavirus vaccine distributed, and on the opportunity of a large sample size because of mass immunisation.",
            "startOffset": 26184,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 29485,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0025",
            "sentence": "An increase in the cumulative incidence of FC within 5\u201312 days after the first dose of Priorix tetra compared to MMR/MMR+V was observed, equating to one additional case of FC per 2747 subjects vaccinated.",
            "startOffset": 29281,
            "title": "Measles-mumps-rubella-varicella (MMRV) vaccine and febrile convulsion (FC)"
        },
        {
            "endOffset": 40068,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 40067,
                    "startOffset": 40063
                }
            },
            "secId": "s0085",
            "sentence": "Some studies required innovative approaches to define an appropriate comparator group [24].",
            "startOffset": 39977,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 39270,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0065",
                    "title": "Responding to a safety signal after licensure"
                },
                {
                    "id": "s0070",
                    "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccines (Arepanrix and Pandemrix)"
                }
            ],
            "secId": "s0080",
            "sentence": "Based on the entirety of epidemiological data, narcolepsy is included in the RMP of all (AS03) pandemic influenza vaccines as an identified risk, with corresponding pharmacovigilance monitoring measures and an updated PI.",
            "startOffset": 39049,
            "title": "Narcolepsy"
        },
        {
            "endOffset": 42389,
            "parents": [],
            "secId": "s0085",
            "sentence": "The robust evaluation of vaccine benefit-risk in real-world settings can only result from multidisciplinary efforts at the manufacturer\u2019s level but also, importantly, from external collaborations, such as with database owners or public health authorities and research institutions, to facilitate study design and implementation.",
            "startOffset": 42061,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 41444,
            "parents": [],
            "secId": "s0085",
            "sentence": "For any safety signal, it is important to evaluate the entire body of evidence to explore the contribution of bias to the vaccine-event association; in this context, meta-analyses are increasingly valued by regulators to comprehensively evaluate safety profiles, assess dose- or brand-specific risk and class effect, but may be limited by lack of access to original datasets by industry sponsors.",
            "startOffset": 41048,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 31642,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0030",
                    "title": "Investigating a potential risk identified prior to licensure"
                }
            ],
            "secId": "s0035",
            "sentence": "In light of these data, the benefit-risk of Cervarix remains favourable.",
            "startOffset": 31570,
            "title": "AS04-adjuvanted human papillomavirus (HPV) vaccine and spontaneous abortion (SA)"
        },
        {
            "endOffset": 25206,
            "parents": [],
            "secId": "s0005",
            "sentence": "The aim of this manuscript is to illustrate these challenges through the description of PASS that contributed to important updates to the safety profile at various stages of the vaccine lifecycle.",
            "startOffset": 25010,
            "title": "Introduction"
        },
        {
            "endOffset": 37257,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0065",
                    "title": "Responding to a safety signal after licensure"
                },
                {
                    "id": "s0070",
                    "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccines (Arepanrix and Pandemrix)"
                }
            ],
            "refoffsets": {
                "b0185": {
                    "endOffset": 37256,
                    "startOffset": 37252
                }
            },
            "secId": "s0075",
            "sentence": "The consistent range of incidence rate ratios around 1.0 with upper 95% confidence limits around 2.0 suggested no evidence of an increased risk following immunisation with Pandemix [37].",
            "startOffset": 37071,
            "title": "Solid organ transplant rejection (SOTR)"
        },
        {
            "endOffset": 34746,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "refoffsets": {
                "b0165": {
                    "endOffset": 34671,
                    "startOffset": 34667
                },
                "b0170": {
                    "endOffset": 34745,
                    "startOffset": 34741
                }
            },
            "secId": "s0055",
            "sentence": "The study showed that Pandemrix was generally well-tolerated with a clinically acceptable safety profile [33], and was not associated with increased adverse outcomes in pregnancy [34].",
            "startOffset": 34562,
            "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine (Pandemrix) and general safety outcomes"
        },
        {
            "endOffset": 36177,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "secId": "s0060",
            "sentence": "Both studies are intended to be conducted in the same settings and with the same methodology.",
            "startOffset": 36084,
            "title": "Malaria RTS,S-AS01 adjuvanted vaccine and AESI"
        },
        {
            "endOffset": 42060,
            "parents": [],
            "refoffsets": {
                "b0230": {
                    "endOffset": 42059,
                    "startOffset": 42055
                }
            },
            "secId": "s0085",
            "sentence": "These examples highlight the increasing complexity of post-licensure plans (e.g., because of new target groups, or novel adjuvants) that require balance between innovative designs, operational feasibility, and public health and regulatory considerations [46].",
            "startOffset": 41801,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 40866,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 40865,
                    "startOffset": 40861
                },
                "b0205": {
                    "endOffset": 40799,
                    "startOffset": 40792
                },
                "b0210": {
                    "endOffset": 40799,
                    "startOffset": 40792
                }
            },
            "secId": "s0085",
            "sentence": "Some studies that were EMA commitments had to be conducted outside of Europe [41,42] or inversely, some FDA requirements were addressed in Europe [24].",
            "startOffset": 40715,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 38022,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0065",
                    "title": "Responding to a safety signal after licensure"
                },
                {
                    "id": "s0070",
                    "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccines (Arepanrix and Pandemrix)"
                }
            ],
            "refoffsets": {
                "b0195": {
                    "endOffset": 38021,
                    "startOffset": 38014
                },
                "b0200": {
                    "endOffset": 38021,
                    "startOffset": 38014
                }
            },
            "secId": "s0080",
            "sentence": "Towards the end of the pandemic vaccination campaigns, cases of narcolepsy, a rare sleep disorder, were reported initially in Sweden and Finland [39,40].",
            "startOffset": 37869,
            "title": "Narcolepsy"
        },
        {
            "endOffset": 44331,
            "parents": [],
            "secId": "s0100",
            "sentence": "LB was employed by the GSK group of companies for most of the period of manuscript development, and currently holds shares in the GSK group of companies.",
            "startOffset": 44178,
            "title": "Competing interests"
        },
        {
            "endOffset": 31243,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0030",
                    "title": "Investigating a potential risk identified prior to licensure"
                }
            ],
            "secId": "s0035",
            "sentence": "The remote vaccination in this referent cohort was to mitigate the incomplete vaccination records, increasing comparability.",
            "startOffset": 31119,
            "title": "AS04-adjuvanted human papillomavirus (HPV) vaccine and spontaneous abortion (SA)"
        },
        {
            "endOffset": 32630,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0040",
                    "title": "Investigating a theoretical risk"
                }
            ],
            "secId": "s0045",
            "sentence": "Blinded case ascertainment was performed.",
            "startOffset": 32589,
            "title": "HPV vaccine and autoimmune diseases"
        },
        {
            "endOffset": 28791,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0025",
            "sentence": "This was considered a potential signal for Priorix tetra and a cohort study based on hospitalisation claims was conducted in the German Pharmacoepidemiological Research Database in children between 9 and 30 months of age, building on the equivalent use of the two antigen combinations, MMR and MMR+V, in Germany.",
            "startOffset": 28479,
            "title": "Measles-mumps-rubella-varicella (MMRV) vaccine and febrile convulsion (FC)"
        },
        {
            "endOffset": 26777,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0020",
            "sentence": "In addition, at the time of US approval, the US Food and Drug Administration (FDA) requested a PASS in a US population.",
            "startOffset": 26658,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 43819,
            "parents": [],
            "secId": "s0095",
            "sentence": "LB and CC initiated and designed the article.",
            "startOffset": 43774,
            "title": "Contributions"
        },
        {
            "endOffset": 33369,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0040",
                    "title": "Investigating a theoretical risk"
                }
            ],
            "refoffsets": {
                "b0150": {
                    "endOffset": 33368,
                    "startOffset": 33364
                }
            },
            "secId": "s0045",
            "sentence": "This was addressed through a meta-analysis of clinical and observational studies which is ongoing [30].",
            "startOffset": 33266,
            "title": "HPV vaccine and autoimmune diseases"
        },
        {
            "endOffset": 23823,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 23822,
                    "startOffset": 23819
                }
            },
            "secId": "s0005",
            "sentence": "They identify, characterise or quantify an identified, potential or theoretical safety hazard; confirm the safety profile of an authorised product; or measure the effectiveness of risk mitigation measures under real-world conditions and contribute to the benefit-risk evaluation of medicinal products [3].",
            "startOffset": 23518,
            "title": "Introduction"
        },
        {
            "endOffset": 34362,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "refoffsets": {
                "b0165": {
                    "endOffset": 34361,
                    "startOffset": 34357
                }
            },
            "secId": "s0055",
            "sentence": "A prospective PASS was conducted in UK general practices in 9143 subjects exposed to Pandemrix, followed up to 6 months for medically-attended AEs occurring within 31 days, serious AEs, and AEs of special interest (AESI) [33].",
            "startOffset": 34136,
            "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine (Pandemrix) and general safety outcomes"
        },
        {
            "endOffset": 36083,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "secId": "s0060",
            "sentence": "The list of AESI was developed in collaboration with paediatric experts.",
            "startOffset": 36011,
            "title": "Malaria RTS,S-AS01 adjuvanted vaccine and AESI"
        },
        {
            "endOffset": 35708,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "secId": "s0060",
            "sentence": "The RMP includes two prospective cohort studies.",
            "startOffset": 35660,
            "title": "Malaria RTS,S-AS01 adjuvanted vaccine and AESI"
        },
        {
            "endOffset": 22972,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 22971,
                    "startOffset": 22968
                }
            },
            "secId": "s0005",
            "sentence": "Whilst most common drug adverse reactions are identified during clinical development, rare adverse events (AEs) may remain undetected or unconfirmed until post-marketing use [1].",
            "startOffset": 22794,
            "title": "Introduction"
        },
        {
            "endOffset": 30853,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0030",
                    "title": "Investigating a potential risk identified prior to licensure"
                }
            ],
            "secId": "s0035",
            "sentence": "Feasibility assessment showed that only a fraction of HPV vaccinations were recorded, therefore only pregnancies in vaccinated women were included.",
            "startOffset": 30706,
            "title": "AS04-adjuvanted human papillomavirus (HPV) vaccine and spontaneous abortion (SA)"
        },
        {
            "endOffset": 43761,
            "parents": [],
            "secId": "s0090",
            "sentence": "Rotateq and Proquad are trademarks of Merck.",
            "startOffset": 43717,
            "title": "Trademark statement"
        },
        {
            "endOffset": 33265,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0040",
                    "title": "Investigating a theoretical risk"
                }
            ],
            "refoffsets": {
                "b0145": {
                    "endOffset": 33264,
                    "startOffset": 33260
                }
            },
            "secId": "s0045",
            "sentence": "Although sensitivity analyses using alternate case definitions and a post hoc self-controlled case series analysis did not confirm these findings, further investigation was requested by EMA due to similar results reported in a study in France [29].",
            "startOffset": 33017,
            "title": "HPV vaccine and autoimmune diseases"
        },
        {
            "endOffset": 24202,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 24201,
                    "startOffset": 24196
                },
                "b0020": {
                    "endOffset": 24201,
                    "startOffset": 24196
                },
                "b0025": {
                    "endOffset": 24201,
                    "startOffset": 24196
                },
                "b0030": {
                    "endOffset": 24201,
                    "startOffset": 24196
                }
            },
            "secId": "s0005",
            "sentence": "In Europe, PASS are defined in the guideline on Good Pharmacovigilance Practices, which has contributed to improving the quality and transparency of PASS while introducing additional procedural steps [3\u20136].",
            "startOffset": 23996,
            "title": "Introduction"
        },
        {
            "endOffset": 43231,
            "parents": [],
            "secId": "s0085",
            "sentence": "Such endeavours including large multinational collaborations are suitable, while alternative approaches such as near real-time monitoring, although not excluding signal confirmation through conventional PASS, are increasingly considered.",
            "startOffset": 42994,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 33438,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0040",
                    "title": "Investigating a theoretical risk"
                }
            ],
            "secId": "s0045",
            "sentence": "At this time, there is no change to the benefit-risk of the vaccine.",
            "startOffset": 33370,
            "title": "HPV vaccine and autoimmune diseases"
        },
        {
            "endOffset": 25792,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0020",
            "sentence": "In view of this identified risk, the safety of new rotavirus vaccines had to be assessed.",
            "startOffset": 25703,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 38275,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0065",
                    "title": "Responding to a safety signal after licensure"
                },
                {
                    "id": "s0070",
                    "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccines (Arepanrix and Pandemrix)"
                }
            ],
            "refoffsets": {
                "b0195": {
                    "endOffset": 38185,
                    "startOffset": 38178
                },
                "b0200": {
                    "endOffset": 38185,
                    "startOffset": 38178
                }
            },
            "secId": "s0080",
            "sentence": "Numerous epidemiological investigations were conducted by national European agencies [39,40] and accumulated epidemiological data suggest an increased risk associated with Pandemrix.",
            "startOffset": 38093,
            "title": "Narcolepsy"
        },
        {
            "endOffset": 37070,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0065",
                    "title": "Responding to a safety signal after licensure"
                },
                {
                    "id": "s0070",
                    "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccines (Arepanrix and Pandemrix)"
                }
            ],
            "secId": "s0075",
            "sentence": "In response to a SOTR signal generated from spontaneous reports in transplanted patients immunised with Arepanrix in Canada and Pandemrix in Europe, a self-controlled case-series was conducted in the CPRD and HES in 91 subjects with a transplant rejection.",
            "startOffset": 36814,
            "title": "Solid organ transplant rejection (SOTR)"
        },
        {
            "endOffset": 38464,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0065",
                    "title": "Responding to a safety signal after licensure"
                },
                {
                    "id": "s0070",
                    "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccines (Arepanrix and Pandemrix)"
                }
            ],
            "secId": "s0080",
            "sentence": "A PASS was conducted in Quebec, Canada, a country where there was no signal, to investigate differences between the safety profiles of Arepanrix and Pandemrix and a potential class effect.",
            "startOffset": 38276,
            "title": "Narcolepsy"
        },
        {
            "endOffset": 43680,
            "parents": [],
            "secId": "s0090",
            "sentence": "Arepanrix, Cervarix, Pandemrix, Mosquirix, Rotarix and Priorix are trademarks owned by or licensed to the GSK group of companies.",
            "startOffset": 43551,
            "title": "Trademark statement"
        },
        {
            "endOffset": 36010,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "refoffsets": {
                "b0180": {
                    "endOffset": 35895,
                    "startOffset": 35891
                }
            },
            "secId": "s0060",
            "sentence": "The first study is collecting baseline incidence data of pre-defined AESI and other AEs leading to hospitalisation or death in at least 30,000 subjects before vaccine implementation [36], whereas the second study will monitor the occurrence of the same pre-defined events after vaccine implementation.",
            "startOffset": 35709,
            "title": "Malaria RTS,S-AS01 adjuvanted vaccine and AESI"
        },
        {
            "endOffset": 32891,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0040",
                    "title": "Investigating a theoretical risk"
                }
            ],
            "refoffsets": {
                "b0140": {
                    "endOffset": 32890,
                    "startOffset": 32886
                }
            },
            "secId": "s0045",
            "sentence": "The results showed no evidence of an increased risk of neuroinflammatory/ophthalmic autoimmune diseases or other autoimmune diseases [28].",
            "startOffset": 32753,
            "title": "HPV vaccine and autoimmune diseases"
        },
        {
            "endOffset": 25009,
            "parents": [],
            "secId": "s0005",
            "sentence": "PASS designs are influenced by numerous factors including vaccine uptake, target population, validity of exposure and outcome data, availability of surveillance systems and relevant data sources, availability of covariate data to address bias and confounding, and methodological and operational feasibility (Table 1).",
            "startOffset": 24692,
            "title": "Introduction"
        },
        {
            "endOffset": 31118,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0030",
                    "title": "Investigating a potential risk identified prior to licensure"
                }
            ],
            "secId": "s0035",
            "sentence": "Outcomes were compared between pregnancies where vaccination occurred near pregnancy onset (from 30 days before, to 90 days after any vaccine dose) and pregnancies where vaccination occurred long before (between 120 days and 18 months after the last vaccine dose).",
            "startOffset": 30854,
            "title": "AS04-adjuvanted human papillomavirus (HPV) vaccine and spontaneous abortion (SA)"
        },
        {
            "endOffset": 42666,
            "parents": [],
            "secId": "s0085",
            "sentence": "A major issue, particularly with secondary data, is governance aspects relating to data accessibility by industry sponsors.",
            "startOffset": 42543,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 23403,
            "parents": [],
            "secId": "s0005",
            "sentence": "Vaccine safety profiles may change over time through expanded use in real-world settings and their systematic monitoring is a continuous process performed in consultation with regulatory authorities.",
            "startOffset": 23204,
            "title": "Introduction"
        },
        {
            "endOffset": 35659,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "refoffsets": {
                "b0175": {
                    "endOffset": 35658,
                    "startOffset": 35654
                }
            },
            "secId": "s0060",
            "sentence": "Robust background incidence data for AESI are necessary to investigate outcomes identified as potential or theoretical risks after vaccine introduction [35].",
            "startOffset": 35502,
            "title": "Malaria RTS,S-AS01 adjuvanted vaccine and AESI"
        },
        {
            "endOffset": 28478,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "refoffsets": {
                "b0090": {
                    "endOffset": 28477,
                    "startOffset": 28473
                }
            },
            "secId": "s0025",
            "sentence": "A post-marketing study with Merck\u2019s ProQuad showed an increased risk of FC after MMRV as compared to MMR vaccination [18].",
            "startOffset": 28356,
            "title": "Measles-mumps-rubella-varicella (MMRV) vaccine and febrile convulsion (FC)"
        },
        {
            "endOffset": 27985,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 27984,
                    "startOffset": 27980
                }
            },
            "secId": "s0020",
            "sentence": "Considering accumulated evidence and the well-documented benefit of the vaccines, the benefit-risk of rotavirus vaccines remains favourable [16].",
            "startOffset": 27840,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 29172,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0025",
            "sentence": "Other challenges included incomplete country coverage of the database and no access outside of academic groups.",
            "startOffset": 29061,
            "title": "Measles-mumps-rubella-varicella (MMRV) vaccine and febrile convulsion (FC)"
        },
        {
            "endOffset": 43532,
            "parents": [],
            "secId": "s0085",
            "sentence": "In conclusion, sustained dialogue with regulatory agencies throughout the vaccine lifecycle and synergistic efforts between vaccine manufacturers and relevant stakeholders should facilitate more rapid and holistic investigation of safety concerns, and their timely communication to the general public.",
            "startOffset": 43231,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 42542,
            "parents": [],
            "secId": "s0085",
            "sentence": "Given their methodological and logistical complexity, PASS are often lengthy in a context where prompt answers to emerging safety concerns are required.",
            "startOffset": 42390,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 27392,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0020",
            "sentence": "However, the study was not powered to assess the risk of IS during the 7 days following vaccination.",
            "startOffset": 27292,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 26931,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "refoffsets": {
                "b0065": {
                    "endOffset": 26930,
                    "startOffset": 26926
                }
            },
            "secId": "s0020",
            "sentence": "A cohort study was conducted using the Optum Research Database and the HealthCore Integrated Research Database, two large US health insurance plans [13].",
            "startOffset": 26778,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 27024,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0020",
            "sentence": "Although IS is a rare outcome, case definition and background incidence data were available.",
            "startOffset": 26932,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 30096,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0030",
                    "title": "Investigating a potential risk identified prior to licensure"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 30036,
                    "startOffset": 30032
                }
            },
            "secId": "s0035",
            "sentence": "An analysis of two Phase III studies could not rule out an increased risk of SA in women unexpectedly exposed during early pregnancy [21] and the FDA requested a PASS to investigate these findings.",
            "startOffset": 29899,
            "title": "AS04-adjuvanted human papillomavirus (HPV) vaccine and spontaneous abortion (SA)"
        },
        {
            "endOffset": 41048,
            "parents": [],
            "refoffsets": {
                "b0225": {
                    "endOffset": 40918,
                    "startOffset": 40914
                }
            },
            "secId": "s0085",
            "sentence": "It is recommended that feasibility assessments [45], as well as a priori planning of sensitivity analyses, become best practice and routine steps in the planning and design of PASS.",
            "startOffset": 40867,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 27839,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "refoffsets": {
                "b0070": {
                    "endOffset": 27838,
                    "startOffset": 27831
                },
                "b0075": {
                    "endOffset": 27838,
                    "startOffset": 27831
                }
            },
            "secId": "s0020",
            "sentence": "The meta-analyses confirmed an association with IS 7 days after the first dose, and to a lesser extent after the second dose; the risk appeared similar for both vaccines [14,15].",
            "startOffset": 27661,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 30235,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0030",
                    "title": "Investigating a potential risk identified prior to licensure"
                }
            ],
            "refoffsets": {
                "b0110": {
                    "endOffset": 30234,
                    "startOffset": 30230
                }
            },
            "secId": "s0035",
            "sentence": "The design had to consider low vaccine exposure in pregnant women and how to identify SA events and their corresponding risk windows [22].",
            "startOffset": 30097,
            "title": "AS04-adjuvanted human papillomavirus (HPV) vaccine and spontaneous abortion (SA)"
        },
        {
            "endOffset": 33755,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "secId": "s0055",
            "sentence": "GSK\u2019s (AS03) A/H1N1 2009 pandemic influenza vaccines were developed in response to the 2009 A/H1N1 pandemic and registered on the basis of clinical experience with (AS03) A/H5N1 vaccines.",
            "startOffset": 33568,
            "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine (Pandemrix) and general safety outcomes"
        },
        {
            "endOffset": 32588,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0040",
                    "title": "Investigating a theoretical risk"
                }
            ],
            "secId": "s0045",
            "sentence": "The male comparator was to address a potential change over time in reporting of the outcomes.",
            "startOffset": 32495,
            "title": "HPV vaccine and autoimmune diseases"
        },
        {
            "endOffset": 23995,
            "parents": [],
            "secId": "s0005",
            "sentence": "Important improvements to monitoring requirements for vaccine safety have been made over the last decade (Fig. 1) and have impacted how vaccine manufacturers conduct PASS.",
            "startOffset": 23824,
            "title": "Introduction"
        },
        {
            "endOffset": 37852,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0065",
                    "title": "Responding to a safety signal after licensure"
                },
                {
                    "id": "s0070",
                    "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccines (Arepanrix and Pandemrix)"
                }
            ],
            "refoffsets": {
                "b0190": {
                    "endOffset": 37851,
                    "startOffset": 37847
                }
            },
            "secId": "s0075",
            "sentence": "Based on overall findings supporting an acceptable safety profile for Pandemrix in transplanted patients, SOTR as a potential risk was removed from the RMPs of A/H1N1 and future (AS03) pandemic influenza vaccines [38].",
            "startOffset": 37634,
            "title": "Solid organ transplant rejection (SOTR)"
        },
        {
            "endOffset": 39545,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 39544,
                    "startOffset": 39541
                }
            },
            "secId": "s0085",
            "sentence": "The described studies share challenges that reflect most of the methodological components of PASS (Table 1), including availability of valid data sources and the need to minimise bias and confounding to the highest extent possible [7].",
            "startOffset": 39310,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 25702,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 25701,
                    "startOffset": 25698
                }
            },
            "secId": "s0020",
            "sentence": "The vaccine was subsequently withdrawn [9].",
            "startOffset": 25659,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 34135,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "refoffsets": {
                "b0160": {
                    "endOffset": 34134,
                    "startOffset": 34130
                }
            },
            "secId": "s0055",
            "sentence": "The EMA requested a series of studies as part of the Risk Management Plan (RMP) of all pandemic influenza vaccines to evaluate safety in the general population and in high-risk groups [32].",
            "startOffset": 33946,
            "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine (Pandemrix) and general safety outcomes"
        },
        {
            "endOffset": 37633,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0065",
                    "title": "Responding to a safety signal after licensure"
                },
                {
                    "id": "s0070",
                    "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccines (Arepanrix and Pandemrix)"
                }
            ],
            "secId": "s0075",
            "sentence": "This study fitted into a comprehensive assessment of the signal, including investigation of immunological mechanisms and signal strengthening methods.",
            "startOffset": 37483,
            "title": "Solid organ transplant rejection (SOTR)"
        },
        {
            "endOffset": 26183,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0020",
            "sentence": "At the time of first Rotarix registration in Latin America, GSK committed to the European Medicines Agency (EMA) to conduct a study in Mexico, one of the first countries to include rotavirus vaccination in their national vaccination calendar.",
            "startOffset": 25941,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 23517,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 23516,
                    "startOffset": 23513
                }
            },
            "secId": "s0005",
            "sentence": "Post-authorisation safety studies (PASS) are the ultimate step of the iterative process of pharmacovigilance [2].",
            "startOffset": 23404,
            "title": "Introduction"
        },
        {
            "endOffset": 32752,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0040",
                    "title": "Investigating a theoretical risk"
                }
            ],
            "secId": "s0045",
            "sentence": "Because of low incidence of individual diseases, two co-primary composite endpoints were defined to reach adequate power.",
            "startOffset": 32631,
            "title": "HPV vaccine and autoimmune diseases"
        },
        {
            "endOffset": 29619,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 29618,
                    "startOffset": 29614
                }
            },
            "secId": "s0025",
            "sentence": "Although the results did not indicate a change in benefit-risk for Priorix tetra as a first dose, a warning was added to the PI [20].",
            "startOffset": 29486,
            "title": "Measles-mumps-rubella-varicella (MMRV) vaccine and febrile convulsion (FC)"
        },
        {
            "endOffset": 38092,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0065",
                    "title": "Responding to a safety signal after licensure"
                },
                {
                    "id": "s0070",
                    "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccines (Arepanrix and Pandemrix)"
                }
            ],
            "secId": "s0080",
            "sentence": "Early investigations suggested a temporal association with Pandemrix.",
            "startOffset": 38023,
            "title": "Narcolepsy"
        },
        {
            "endOffset": 35280,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "secId": "s0060",
            "sentence": "In October 2015, the World Health Organization recommended a pilot implementation in 3\u20135 distinct epidemiological settings in sub-Saharan Africa with moderate-to-high malaria transmission.",
            "startOffset": 35092,
            "title": "Malaria RTS,S-AS01 adjuvanted vaccine and AESI"
        },
        {
            "endOffset": 41800,
            "parents": [],
            "secId": "s0085",
            "sentence": "The last decade has fostered learnings from regulatory commitments for several vaccines.",
            "startOffset": 41712,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 28899,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "refoffsets": {
                "b0095": {
                    "endOffset": 28898,
                    "startOffset": 28894
                }
            },
            "secId": "s0025",
            "sentence": "The study compared those who had received a first dose of MMRV to those who received MMR and/or MMR+V [19].",
            "startOffset": 28792,
            "title": "Measles-mumps-rubella-varicella (MMRV) vaccine and febrile convulsion (FC)"
        },
        {
            "endOffset": 40284,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 40206,
                    "startOffset": 40199
                },
                "b0220": {
                    "endOffset": 40206,
                    "startOffset": 40199
                }
            },
            "secId": "s0085",
            "sentence": "Database studies pose specific challenges and should include case validation by independent experts blinded to vaccination status [27,44] to avoid misclassification bias if disease status is incorrectly categorised.",
            "startOffset": 40069,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 31569,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0030",
                    "title": "Investigating a potential risk identified prior to licensure"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 31568,
                    "startOffset": 31564
                }
            },
            "secId": "s0035",
            "sentence": "Observed SA rates were consistent with published background rates and there was no evidence of an increased risk of SA or other pregnancy outcomes in young women inadvertently exposed around gestation compared to other women [24].",
            "startOffset": 31339,
            "title": "AS04-adjuvanted human papillomavirus (HPV) vaccine and spontaneous abortion (SA)"
        },
        {
            "endOffset": 41711,
            "parents": [],
            "refoffsets": {
                "b0230": {
                    "endOffset": 41710,
                    "startOffset": 41706
                }
            },
            "secId": "s0085",
            "sentence": "Vaccine manufacturers, regulatory agencies, academic institutions, and (supra)national public health authorities have a common interest in ensuring that PASS are designed and properly executed to generate robust data addressing important public health questions [46].",
            "startOffset": 41444,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 39048,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0065",
                    "title": "Responding to a safety signal after licensure"
                },
                {
                    "id": "s0070",
                    "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccines (Arepanrix and Pandemrix)"
                }
            ],
            "refoffsets": {
                "b0200": {
                    "endOffset": 39047,
                    "startOffset": 39043
                }
            },
            "secId": "s0080",
            "sentence": "Challenges were inherent to the complex natural history of narcolepsy and the general inability to account for confounders [40].",
            "startOffset": 38920,
            "title": "Narcolepsy"
        },
        {
            "endOffset": 39810,
            "parents": [],
            "secId": "s0085",
            "sentence": "Independent of study design or type of data collection, a common challenge is scarcity of data on the aetiology and incidence of rare events (e.g., immune-mediated diseases, rare pregnancy outcomes), particularly in regions such as low and middle income countries.",
            "startOffset": 39546,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 35501,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "secId": "s0060",
            "sentence": "Background incidence data of AESI are scarce in sub-Saharan African countries where large healthcare databases are not available and pharmacovigilance systems are either in development, poorly functional or non-existent.",
            "startOffset": 35281,
            "title": "Malaria RTS,S-AS01 adjuvanted vaccine and AESI"
        },
        {
            "endOffset": 40714,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 40583,
                    "startOffset": 40579
                }
            },
            "secId": "s0085",
            "sentence": "Sufficient vaccine uptake in the region or population of interest is a crucial factor that can lead to suboptimal sample size due to low market share [24], low vaccination compliance, or conversely, to issues in accruing unexposed subjects in countries with universal mass vaccination.",
            "startOffset": 40429,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 43970,
            "parents": [],
            "secId": "s0095",
            "sentence": "All authors were involved in assembling and interpreting the information and in developing this manuscript, and gave final approval before submission.",
            "startOffset": 43820,
            "title": "Contributions"
        },
        {
            "endOffset": 33945,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "refoffsets": {
                "b0155": {
                    "endOffset": 33944,
                    "startOffset": 33940
                }
            },
            "secId": "s0055",
            "sentence": "Limited safety data were available at the time of registering A/H1N1 2009 pandemic vaccines since their development was accelerated based on experience with H5N1 pre-pandemic vaccines [31].",
            "startOffset": 33756,
            "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine (Pandemrix) and general safety outcomes"
        },
        {
            "endOffset": 30497,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0030",
                    "title": "Investigating a potential risk identified prior to licensure"
                }
            ],
            "secId": "s0035",
            "sentence": "After cancelling a prospective study in the US due to low vaccine uptake leading to insufficient sample size, a retrospective cohort study was conducted in the United Kingdom (UK), which had achieved high coverage as part of the national immunisation programme.",
            "startOffset": 30236,
            "title": "AS04-adjuvanted human papillomavirus (HPV) vaccine and spontaneous abortion (SA)"
        },
        {
            "endOffset": 38722,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0065",
                    "title": "Responding to a safety signal after licensure"
                },
                {
                    "id": "s0070",
                    "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccines (Arepanrix and Pandemrix)"
                }
            ],
            "secId": "s0080",
            "sentence": "The choice of Canada was also driven by lack of access to most European data sources; the fact that potential bias due to public and regulatory attention in Europe was marginal; and the opportunity of primary data collection and a H1N1 vaccination registry.",
            "startOffset": 38465,
            "title": "Narcolepsy"
        },
        {
            "endOffset": 30705,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0030",
                    "title": "Investigating a potential risk identified prior to licensure"
                }
            ],
            "refoffsets": {
                "b0115": {
                    "endOffset": 30704,
                    "startOffset": 30700
                }
            },
            "secId": "s0035",
            "sentence": "The study used the Clinical Practice Research Datalink (CPRD), a large representative healthcare database of general practitioners with adequate medical and immunisation records, and a mother\u2013baby link [23].",
            "startOffset": 30498,
            "title": "AS04-adjuvanted human papillomavirus (HPV) vaccine and spontaneous abortion (SA)"
        },
        {
            "endOffset": 27291,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0020",
            "sentence": "No increased risk was observed in the 0\u201359-day risk period following Rotarix.",
            "startOffset": 27214,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 36349,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "secId": "s0060",
            "sentence": "To maximise case detection, the studies include active surveillance through home visits, outpatient visits and hospitalisations, and enhanced hospitalisation surveillance.",
            "startOffset": 36178,
            "title": "Malaria RTS,S-AS01 adjuvanted vaccine and AESI"
        },
        {
            "endOffset": 27164,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0020",
            "sentence": "A large vaccinated cohort was matched to a concurrent and a historical cohort of infants having received an inactivated poliovirus vaccine.",
            "startOffset": 27025,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 28953,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0025",
            "sentence": "The case definition of FC was based on billing codes.",
            "startOffset": 28900,
            "title": "Measles-mumps-rubella-varicella (MMRV) vaccine and febrile convulsion (FC)"
        },
        {
            "endOffset": 27213,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0020",
            "sentence": "IS cases were confirmed by medical chart review.",
            "startOffset": 27165,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 33016,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0040",
                    "title": "Investigating a theoretical risk"
                }
            ],
            "secId": "s0045",
            "sentence": "However, secondary analysis of individual diseases showed an increased risk of autoimmune thyroiditis in the exposed cohort.",
            "startOffset": 32892,
            "title": "HPV vaccine and autoimmune diseases"
        },
        {
            "endOffset": 29280,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0025",
            "sentence": "Risk of misclassification of exposure or outcome had been mitigated by pre-planned feasibility assessments.",
            "startOffset": 29173,
            "title": "Measles-mumps-rubella-varicella (MMRV) vaccine and febrile convulsion (FC)"
        },
        {
            "endOffset": 25314,
            "parents": [],
            "secId": "s0010",
            "sentence": "The main results and primary challenges of each selected PASS is shown in Table 2.",
            "startOffset": 25232,
            "title": "Selected examples of PASS"
        },
        {
            "endOffset": 34805,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "secId": "s0055",
            "sentence": "No changes to the PI or RMP were made based on this study.",
            "startOffset": 34747,
            "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine (Pandemrix) and general safety outcomes"
        },
        {
            "endOffset": 43716,
            "parents": [],
            "secId": "s0090",
            "sentence": "RotaShield is a trademark of Wyeth.",
            "startOffset": 43681,
            "title": "Trademark statement"
        },
        {
            "endOffset": 24415,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 24414,
                    "startOffset": 24411
                }
            },
            "secId": "s0005",
            "sentence": "The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance has provided an opportunity to improve post-licensure research through methodological standards, checklists and a study register [7].",
            "startOffset": 24203,
            "title": "Introduction"
        },
        {
            "endOffset": 40428,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 40427,
                    "startOffset": 40411
                },
                "b0140": {
                    "endOffset": 40427,
                    "startOffset": 40411
                },
                "b0185": {
                    "endOffset": 40427,
                    "startOffset": 40411
                },
                "b0190": {
                    "endOffset": 40427,
                    "startOffset": 40411
                },
                "b0225": {
                    "endOffset": 40427,
                    "startOffset": 40411
                }
            },
            "secId": "s0085",
            "sentence": "For some studies, feasibility assessments substantially helped determine whether the study could timely achieve its objectives [24,28,37,38,45].",
            "startOffset": 40284,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 25658,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0020",
            "sentence": "After marketing of the first tetravalent rhesus-human reassortant rotavirus vaccine (RotaShield, Wyeth, Pennsylvania, US), an increased risk of IS in infants was observed during the first week after immunisation.",
            "startOffset": 25446,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 44177,
            "parents": [],
            "secId": "s0100",
            "sentence": "CC, DR, M-NM, SF, HB and VB hold shares in the GSK group of companies as part of their employee remuneration.",
            "startOffset": 44068,
            "title": "Competing interests"
        },
        {
            "endOffset": 29060,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0025",
            "sentence": "Since medical chart review was not possible, definitions of varying sensitivity and specificity were used.",
            "startOffset": 28954,
            "title": "Measles-mumps-rubella-varicella (MMRV) vaccine and febrile convulsion (FC)"
        },
        {
            "endOffset": 36632,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "secId": "s0060",
            "sentence": "These studies are associated with capacity building to support, with local authorities, the development of a surveillance system including establishment of a telemedicine system, provision of specialised training, laboratory materials and support, and mobile-phone reporting of AEs.",
            "startOffset": 36350,
            "title": "Malaria RTS,S-AS01 adjuvanted vaccine and AESI"
        },
        {
            "endOffset": 29898,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0030",
                    "title": "Investigating a potential risk identified prior to licensure"
                }
            ],
            "secId": "s0035",
            "sentence": "The AS04-HPV-16/18-vaccine (Cervarix, GSK) is indicated in young women to prevent premalignant genital lesions and cervical cancer.",
            "startOffset": 29767,
            "title": "AS04-adjuvanted human papillomavirus (HPV) vaccine and spontaneous abortion (SA)"
        },
        {
            "endOffset": 44454,
            "parents": [],
            "secId": "s0105",
            "sentence": "GlaxoSmithKline Biologicals SA covered all costs associated with the development and publication of this manuscript.",
            "startOffset": 44338,
            "title": "Funding"
        },
        {
            "endOffset": 35091,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "secId": "s0060",
            "sentence": "The RTS,S-AS01 adjuvanted malaria vaccine (Mosquirix, GSK) was granted positive opinion by the EMA in July 2015 and is indicated for use in infants and young children for the prevention of Plasmodium falciparum malaria and hepatitis B.",
            "startOffset": 34856,
            "title": "Malaria RTS,S-AS01 adjuvanted vaccine and AESI"
        },
        {
            "endOffset": 24691,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 24486,
                    "startOffset": 24483
                }
            },
            "secId": "s0005",
            "sentence": "Similar but more limited guidance exists in the United States (US) [8]; here we will refer to all post-authorisation safety studies using \u2018PASS\u2019 as a generic term, whether they were conducted in Europe or globally, and regardless of the regulatory agency which mandated them.",
            "startOffset": 24416,
            "title": "Introduction"
        },
        {
            "endOffset": 32035,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0040",
                    "title": "Investigating a theoretical risk"
                }
            ],
            "refoffsets": {
                "b0125": {
                    "endOffset": 31872,
                    "startOffset": 31865
                },
                "b0130": {
                    "endOffset": 31872,
                    "startOffset": 31865
                }
            },
            "secId": "s0045",
            "sentence": "In view of the theoretical concern that vaccine adjuvants could trigger the onset or exacerbation of autoimmune diseases in susceptible individuals [25,26] the FDA requested a PASS to investigate the risk of neuroinflammatory/ophthalmic and other autoimmune diseases within 12 months following the first Cervarix dose.",
            "startOffset": 31717,
            "title": "HPV vaccine and autoimmune diseases"
        },
        {
            "endOffset": 25940,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "refoffsets": {
                "b0050": {
                    "endOffset": 25939,
                    "startOffset": 25932
                },
                "b0055": {
                    "endOffset": 25939,
                    "startOffset": 25932
                }
            },
            "secId": "s0020",
            "sentence": "In large pre-licensure studies of Rotarix (GSK, Wavre, Belgium) and Rotateq (Merck, Kenilworth, NJ, US), no increased IS risk was observed [10,11].",
            "startOffset": 25793,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 42993,
            "parents": [],
            "refoffsets": {
                "b0235": {
                    "endOffset": 42992,
                    "startOffset": 42985
                },
                "b0240": {
                    "endOffset": 42992,
                    "startOffset": 42985
                }
            },
            "secId": "s0085",
            "sentence": "Awareness of the need for public\u2013private partnerships such as ADVANCE (Accelerated Development of Vaccine benefit-risk Collaboration in Europe), whose aim is to build a multi-stakeholder sustainable pan-European framework able to rapidly deliver quantitative data for vaccine benefit-risk assessment, has been growing [47,48].",
            "startOffset": 42667,
            "title": "Lessons learned and future perspectives"
        },
        {
            "endOffset": 32161,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0040",
                    "title": "Investigating a theoretical risk"
                }
            ],
            "refoffsets": {
                "b0135": {
                    "endOffset": 32160,
                    "startOffset": 32156
                }
            },
            "secId": "s0045",
            "sentence": "Challenges included the need for robust case validation and for a large exposed cohort given the rarity of the outcomes [27].",
            "startOffset": 32036,
            "title": "HPV vaccine and autoimmune diseases"
        },
        {
            "endOffset": 23203,
            "parents": [],
            "secId": "s0005",
            "sentence": "Unlike most drugs, vaccines are administered to healthy individuals, including young children and vulnerable populations such as individuals with underlying medical conditions or immunosuppression, pregnant women, and the elderly.",
            "startOffset": 22973,
            "title": "Introduction"
        },
        {
            "endOffset": 37482,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0065",
                    "title": "Responding to a safety signal after licensure"
                },
                {
                    "id": "s0070",
                    "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccines (Arepanrix and Pandemrix)"
                }
            ],
            "secId": "s0075",
            "sentence": "EMA\u2019s recommendation was to use the CPRD, expecting prompt data generation; however, challenges included the unexpected complexity of an outcome managed in hospital settings for which all risks factors could not be captured.",
            "startOffset": 37258,
            "title": "Solid organ transplant rejection (SOTR)"
        },
        {
            "endOffset": 27660,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0020",
            "sentence": "As several studies since Rotarix and Rotateq registration suggested an increased risk 7 days\u2019 post-vaccination, meta-analyses were conducted to obtain risk estimates associated with two doses, and to assess whether the risk is brand-specific or rather a class effect.",
            "startOffset": 27393,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 38919,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0065",
                    "title": "Responding to a safety signal after licensure"
                },
                {
                    "id": "s0070",
                    "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccines (Arepanrix and Pandemrix)"
                }
            ],
            "refoffsets": {
                "b0205": {
                    "endOffset": 38918,
                    "startOffset": 38911
                },
                "b0210": {
                    "endOffset": 38918,
                    "startOffset": 38911
                }
            },
            "secId": "s0080",
            "sentence": "The heterogeneity in risk estimates derived from the various methodological approaches in the Quebec study pointed to no strong evidence of an association between Arepanrix and narcolepsy [41,42].",
            "startOffset": 38723,
            "title": "Narcolepsy"
        },
        {
            "endOffset": 44068,
            "parents": [],
            "secId": "s0100",
            "sentence": "CC, CW, DR, FH, M-NM, SF, HB and VB are employed by the GSK group of companies.",
            "startOffset": 43989,
            "title": "Competing interests"
        },
        {
            "endOffset": 26596,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "refoffsets": {
                "b0060": {
                    "endOffset": 26595,
                    "startOffset": 26591
                }
            },
            "secId": "s0020",
            "sentence": "A temporal risk increase was observed within 7 days after the first dose [12].",
            "startOffset": 26518,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 26657,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0015",
                    "title": "Introducing a new vaccine when there is an identified risk with a similar vaccine"
                }
            ],
            "secId": "s0020",
            "sentence": "The warning was updated in the Prescribing Information (PI).",
            "startOffset": 26597,
            "title": "Rotavirus vaccines and intussusception (IS)"
        },
        {
            "endOffset": 34475,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "refoffsets": {
                "b0165": {
                    "endOffset": 34474,
                    "startOffset": 34467
                },
                "b0170": {
                    "endOffset": 34474,
                    "startOffset": 34467
                }
            },
            "secId": "s0055",
            "sentence": "Solicited AEs and pregnancy outcomes were later assessed in the subset of 267 vaccinated pregnant women [33,34].",
            "startOffset": 34363,
            "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine (Pandemrix) and general safety outcomes"
        },
        {
            "endOffset": 32351,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0040",
                    "title": "Investigating a theoretical risk"
                }
            ],
            "secId": "s0045",
            "sentence": "A retrospective cohort study in the CPRD and the linked Hospital Episode Statistics (HES) was feasible due to high vaccine uptake and appropriateness of the database to detect the outcomes.",
            "startOffset": 32162,
            "title": "HPV vaccine and autoimmune diseases"
        },
        {
            "endOffset": 34561,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Selected examples of PASS"
                },
                {
                    "id": "s0050",
                    "title": "Introducing novel vaccines"
                }
            ],
            "secId": "s0055",
            "sentence": "Observed outcomes were compared periodically to background rates from the literature.",
            "startOffset": 34476,
            "title": "Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine (Pandemrix) and general safety outcomes"
        }
    ],
    "docId": "S0264410X17305509",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "catherine.x.cohet@gsk.com",
                "first": "Catherine",
                "initial": "C.",
                "last": "Cohet"
            },
            {
                "email": "dominique.x.rosillon@gsk.com",
                "first": "Dominique",
                "initial": "D.",
                "last": "Rosillon"
            },
            {
                "email": "corinne.x.willame@gsk.com",
                "first": "Corinne",
                "initial": "C.",
                "last": "Willame"
            },
            {
                "email": "Francois.F.Haguinet@gsk.com",
                "first": "Francois",
                "initial": "F.",
                "last": "Haguinet"
            },
            {
                "email": "Marie-Noelle.Marenne@gsk.com",
                "first": "Marie No\u00eblle",
                "initial": "M.N.",
                "last": "Marenne"
            },
            {
                "email": "Sandrine.X.Fontaine@gsk.com",
                "first": "Sandrine",
                "initial": "S.",
                "last": "Fontaine"
            },
            {
                "email": "Hubert.X.Buyse@gsk.com",
                "first": "Hubert",
                "initial": "H.",
                "last": "Buyse"
            },
            {
                "email": "Vincent.G.Bauchau@gsk.com",
                "first": "Vincent",
                "initial": "V.",
                "last": "Bauchau"
            },
            {
                "email": "laurencebaril1@gmail.com",
                "first": "Laurence",
                "initial": "L.",
                "last": "Baril"
            }
        ],
        "doi": "10.1016/j.vaccine.2017.04.058",
        "firstpage": "3041",
        "issn": "0264410X",
        "keywords": [
            "Adverse event",
            "Challenges",
            "PASS",
            "Pharmacoepidemiology",
            "Safety",
            "Vaccine"
        ],
        "lastpage": "3049",
        "openaccess": "Full",
        "pub_year": 2017,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Challenges in conducting post-authorisation safety studies (PASS): A vaccine manufacturer's view"
    }
}